|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 801 PENNSYLVANIA AVENUE NW |
Address2 | SUITE 725 |
| City | WASHINGTON |
State | DC |
Zip Code | 20004 |
Country | USA |
3. Principal place of business (if different than line 2)
| City | Bridgewater |
State | NJ |
Zip Code | 08807 |
Country | USA |
|
5. Senate ID# 56838-12
|
||||||||
|
6. House ID# 351860000
|
||||||||
| TYPE OF REPORT | 8. Year | 2012 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date | |
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Edward Greissing Jr., Vice President, U.S. Corporate Affairs |
Date | 06/14/2013 |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General issues regarding implementation of Public Law 111-148 "Patient Protection and Affordable Care Act" and efforts to repeal PL111-148 provisions that prohibit individuals from using Health Savings Accounts or Flexible Spending Accounts to purchase Over-The-Counter medical products, including such provisions in HR2529 "Restoring Access to Medication Act" and HR436 "Health Care Cost Reduction Act of 2012"; awareness & issues related to diabetes and patient access to diabetes care; S1002 and HR4223
"SAFE DOSES Act" - all provisions; HR2405 and S1855 "Pandemic and All Hazards Preparation Act Reauthorization of 2011" - all provisions; HR3627 and S1884 "School Access to Emergency Epinephrine Act" - all provisions; education and awareness of influenza pandemic and biodefense funding in FY2012 and related international intellectual property issues;education and awareness of dengue.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Mary Anne |
Dunlap |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commcercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Extension of the U.S. R&D tax credit and all such provisions in HR942 "The American Research and Competitiveness Act of 2011" and S1577 "Greater Research Opportunities With Tax Help Act (GROWTH Act)"; and efforts to add Quadrivalent influenza vaccine formulation to the Vaccine Injury Compensation Program
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commcercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ANI
16. Specific lobbying issues
HR3798 "Egg Products Inspection Act Amendments of 2012" - all provisions; issues related to a National Environmental Policy Act (NEPA) exclusion for veterinary biologics; and general issues related to the USDA Wildlife Service Oral Rabies Vaccination Program.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES,
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commcercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ECN
16. Specific lobbying issues
General issues related to foreign direct investment in the United States, including all provisions of S3274 and HR5910 "Global Investment in American Jobs Act of 2012"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Ann |
Taylor |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Sanofi SA, the foreign parent corporation of sanofi-aventis U.S. Inc., as disclosed on its LD-1
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
Discussions related to international intellectual propterty issues.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Patrick |
McLain |
|
|
|
Edward |
Greissing |
Jr. |
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commcercially benefit sanofi-aventis U.S . Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MED
16. Specific lobbying issues
Reauthorization of the Prescription Drug User Fee Act (PDUFA) including potential amendments and all provisions of HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Mary Anne |
Dunlap |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
|
Amy |
Redl |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit.
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MAN
16. Specific lobbying issues
General issues related to prescription drug supply chain, including importation safety, foreign inspections, track and trace, and drug shortage, including related amendments to HR5651 "Food and Drug Administration Reform Act of 2012" and S3187 "Food and Drug Administration Safety and Innovation Act"
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sean |
Callinicos |
|
|
|
Timothy |
Clark |
|
|
|
Mary Anne |
Dunlap |
|
|
|
Edward |
Greissing |
Jr. |
|
|
Patrick |
McLain |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
sanofi-aventis U.S. Inc. is owned by Sanofi SA and to the degree that public policies, either laws or regulations, commercially benefit sanofi-aventis U.S. Inc., so too Sanofi SA, as the parent corporation, will benefit
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |